EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparison of conbercept and ranibizumab for the treatment of idiopathic choroidal neovascularization using optical coherence tomography angiography and multifocal electroretinography

Gaixia Zhai, Lin Zhu, Yuanzhen Su, Zuofen Wang

Frontiers in Pharmacology · 24.06.2026 · 17

DOI: 10.3389/fphar.2026.1854440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 24.06.2026. Verfasst von Gaixia Zhai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Zibo Central Hospital, Zibo, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to compare the efficacies of conbercept and ranibizumab for the treatment of idiopathic choroidal neovascularization (ICNV) using optical coherence tomography angiography (OCTA) and multifocal electroretinography (mfERG).

Methods

Sixty patients with ICNV were retrospectively assessed and followed up in this retrospective comparative cohort study. Thirty patients were assigned to the conbercept group, and 30 patients were assigned to the ranibizumab group. Patients in both groups were treated with 1+ pro re nata. Best-corrected visual acuity (BCVA), macular central retinal thickness (CRT), and CNV blood flow area before treatment and at 1, 3, 6, and 12 months after treatment were obtained. The first positive peak (P1) amplitude density in ring 1 and intraocular pressure (IOP) were recorded at baseline and the last follow-up.

Results

The follow-up duration was 12 months. BCVA (logMAR) improved at 1, 3, 6, and 12 months after the injection, and the CRT and CNV blood flow area significantly decreased in both groups relative to their values before treatment (p < 0.05). The P1 amplitude densities in ring 1 at baseline were 50.97 ± 8.05 nv/deg 2 and 52.50 ± 9.71 nv/deg 2 in the conbercept and ranibizumab groups, respectively (p = 0.5080). The change in the P1 amplitude density from baseline to the last follow-up visit was statistically significant (p < 0.05) in both groups. No significant changes were noted in the BCVA, IOP, CRT, CNV blood flow area, and P1 amplitude density after treatment from the baseline for the two groups. The number of injections was 2.00 ± 1.05 for the conbercept group and 2.67 ± 1.06 for the ranibizumab group (p = 0.0077). No serious ocular complications such as endophthalmitis and systemic adverse reactions such as myocardial infarction or cerebral infarction occurred in both groups.

Conclusion

Compared with intravitreal ranibizumab, intravitreal conbercept had a similar therapeutic effect in improving the structure and function on ICNV but with fewer injections.

Schlagwörter

Stichwörter der Autor:innen

conberceptefficacyidiopathic choroidal neovascularizationmultifocal electroretinographyranibizumabvascular endothelial growth factor

Autor:innen und Institutionen

  • Zibo Central Hospital, Zibo, China.

Zitieren

APA

Zhai, G., Zhu, L., Su, Y., & Wang, Z. (2026). Comparison of conbercept and ranibizumab for the treatment of idiopathic choroidal neovascularization using optical coherence tomography angiography and multifocal electroretinography. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1854440

Vancouver

Zhai G, Zhu L, Su Y, Wang Z. Comparison of conbercept and ranibizumab for the treatment of idiopathic choroidal neovascularization using optical coherence tomography angiography and multifocal electroretinography. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1854440

BibTeX
@article{Zhai2026,
  author = {Zhai, Gaixia and Zhu, Lin and Su, Yuanzhen and Wang, Zuofen},
  title = {Comparison of conbercept and ranibizumab for the treatment of idiopathic choroidal neovascularization using optical coherence tomography angiography and multifocal electroretinography},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1854440}
}
Kostenlos starten →